Search results
Author(s):
Saagar Mahida
,
Benjamin Berte
,
Seigo Yamashita
,
et al
Added:
3 years ago
Since the first catheter ablation for cardiac arrhythmia more than three decades ago, ablation technology has continually evolved at a rapid pace. Much of the early progress in the field was made in ablation of supraventricular tachycardias. Following a seminal study from Haïssaguerre et al.1 in 1998, which demonstrated that pulmonary vein triggers are important sources of atrial fibrillation (AF…
View more
Author(s):
Eyal Nof
,
William G Stevenson
,
Roy John
Added:
3 years ago
Sustained ventricular tachycardia (VT) and ventricular fibrillation (VF) are typically a manifestation of significant structural heart disease and often associated with a high risk of sudden cardiac death. Implantable cardioverter defibrillators (ICDs) remain the mainstay of therapy for prevention of sudden cardiac death associated with these arrhythmias.1 However, ICDs treat the arrhythmia after…
View more
Author(s):
Fouad Khalil
,
Konstantinos C Siontis
,
Gabor Bagameri
,
et al
Added:
3 years ago
Catheter-based ablation has been a well-established tool in the treatment of ventricular tachycardia (VT). However, the effectiveness of catheter ablation may be limited by its ability to access sites of arrhythmogenic tissue and achieve adequate lesion size in target areas without risking collateral damage. Antiarrhythmic surgery would be an effective alternative in such situations. Despite the…
View more
Author(s):
Pok Tin Tang
,
Duc H Do
,
Anthony C Li
,
et al
Added:
3 years ago
Ventricular arrhythmias remain a major contributor to cardiac morbidity and mortality worldwide, despite ongoing research and implementation of novel therapeutic interventions. Modern management of patients with ventricular arrhythmias requires a multidisciplinary team approach, especially in complex presentations with a background of multiple medical comorbidities.1,2 Such teams may include…
View more
Author(s):
Mario Njeim
,
Frank Bogun
Added:
3 years ago
Percutaneous ablation for ventricular tachycardia (VT) was first attempted in 1983 and has rapidly evolved to become an important option for controlling recurrent VTs.1 Endocardial ablation remained the only percutaneous approach until epicardial access was introduced by Sosa et al. in 1996 and thereafter became progressively more available as an adjunctive strategy for the treatment of…
View more
Author(s):
Mouhannad M Sadek
,
Robert D Schaller
,
Gregory E Supple
,
et al
Added:
3 years ago
Scar-related reentrant ventricular tachycardia (VT) may be present in a variety of structural heart disease (SHD) phenotypes. In this setting, VT circuits are comprised of viable myocytes separated by fibrosis, allowing for the slow conduction needed to facilitate reentry.1,2 Aetiologies of fibrosis include ischaemic heart disease (IHD), inflammatory conditions, infiltrative cardiomyopathy,…
View more
Author(s):
Chen Wei
,
Pierre Qian
,
Usha B Tedrow
,
et al
Added:
3 years ago
Ventricular tachycardia (VT) is a life-threatening sequela found in patients with cardiomyopathy. ICDs can terminate ventricular arrhythmias, but recurrent device shocks lead to reduced quality of life and are associated with higher mortality.1–5 Radiofrequency catheter ablation has emerged as an effective treatment for VT refractory to anti-arrhythmic therapy and has also been shown to reduce…
View more
Author(s):
Venkatesh Ravi
,
Jeffrey Winterfield
,
Jackson J Liang
,
et al
Added:
1 year ago